An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers

• Published in: Clinical neuropharmacology Vol. 33; no. 2; p. 55
• Main Authors: Brooks, David J, Papapetropoulos, Spyridon, Vandenhende, Francois, Tomic, Davorka, He, Ping, Coppell, Alex, O'Neill, Gilmore
• Format: Journal Article
• Language: English
• Published: United States 01.03.2010
• Subjects: Adenosine A2 Receptor Antagonists; Adult; Brain - diagnostic imaging; Brain - metabolism; Carbon Radioisotopes - analysis; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Models, Statistical; Positron-Emission Tomography - methods; Pyrazoles - analysis; Pyrimidines - analysis; Pyrimidines - pharmacokinetics; Radioligand Assay - methods; Triazoles - pharmacokinetics

Adenosine A2A receptor antagonists are potential new treatments for Parkinson disease. We used positron emission tomography (PET) of the A2A receptor radiotracer, [C]SCH442416, to assess binding of the novel A2A antagonist, vipadenant (previously known as BIIB014), to human brain A2A receptors and t...